Headlines about Organovo (NASDAQ:ONVO) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Organovo earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 45.8165402758208 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media stories that may have impacted Accern’s scoring:
- Organovo Holdings, Inc. (NASDAQ:ONVO) – Here’s What to Focus on – Nasdaq Journal (nasdaqjournal.com)
- Historical Performances are Key to Consider – Organovo Holdings Inc (NASDAQ: ONVO) – Stocks Pen (stockspen.com)
- Zacks: Analysts Anticipate Organovo Holdings Inc (ONVO) to Announce -$0.07 Earnings Per Share (americanbankingnews.com)
- Analysts recommended an average rating score of 1.70 for Organovo Holdings, Inc. (ONVO) – Wall Street Morning (wallstreetmorning.com)
- Buyers and Sellers Alert – Organovo Holdings, Inc. (ONVO) – Nasdaq Fortune (press release) (nasdaqfortune.com)
Organovo (NASDAQ:ONVO) traded down $0.10 during trading hours on Wednesday, reaching $1.07. 656,432 shares of the company’s stock were exchanged, compared to its average volume of 1,091,319. The firm has a market capitalization of $129.68, a price-to-earnings ratio of -2.97 and a beta of 2.76. Organovo has a 52-week low of $0.93 and a 52-week high of $3.26.
ONVO has been the topic of a number of recent analyst reports. BTIG Research restated a “buy” rating and issued a $3.00 price target on shares of Organovo in a research report on Thursday, November 16th. Zacks Investment Research lowered shares of Organovo from a “buy” rating to a “hold” rating in a research report on Wednesday, December 27th. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. Organovo has an average rating of “Hold” and a consensus price target of $3.40.
Organovo Holdings, Inc is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.